SHC-019 is under clinical development by Nanjing Sanhome Pharmaceutical and currently in Phase I for Liver Cancer. According to GlobalData, Phase I drugs for Liver Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SHC-019’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SHC-019 is under development for the treatment of liver cancer. It acts by targeting TGF-beta.
For a complete picture of SHC-019’s drug-specific PTSR and LoA scores, buy the report here.